ARTICLE | Clinical News
Aronex's Nyotran misses end point
February 16, 2000 8:00 AM UTC
ARNX reported that a 261-patient Phase III study of its Nyotran liposomal nystatin to treat cryptococcal meningitis in HIV patients missed its primary efficacy end point of equivalence to amphotericin...